SOUTH SAN FRANCISCO, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the appointment of Garry Nicholson as chairman of its board of directors. Mr. Nicholson brings more than 30 years of pharmaceutical and biotech oncology experience and previously served as president of Pfizer Oncology where he led its global oncology franchise. Day One co-founder Julie Grant, who served as board chair since 2021, will continue to serve as a member of the board of directors.
“Garry is an accomplished leader in the development and commercialization of new cancer therapies and we are thrilled to welcome him as chairman of our board of directors,” said Jeremy Bender, Ph.D., chief executive officer of Day One. “Garry’s expertise and guidance will be critical as tovorafenib continues to advance in our pivotal FIREFLY-1 trial towards potential commercialization for relapsed pediatric low-grade glioma and as our other ongoing clinical trials continue to progress.”
Mr. Nicholson currently serves as chairman of the board of directors for G1 Therapeutics and as a board member for Tmunity Therapeutics and NextCure. He also previously served on the board of directors for Turning Point Therapeutics, Five Prime Therapeutics and TESARO prior to their acquisitions by large pharmaceutical companies. As former president of Pfizer Oncology, his responsibilities included global commercialization, sales, clinical development, regulatory strategy and business development for Pfizer’s oncology portfolio. Earlier in his career, Mr. Nicholson held various leadership positions in the oncology division of Eli Lilly and Company, including global oncology platform leader. He has also served as president and CEO of XTuit Pharmaceuticals. Mr. Nicholson earned a B.S. in Pharmacy from the University of North Carolina at Chapel Hill and an M.B.A. from the University of South Carolina.
“Day One is an innovative company dedicated to advancing new cancer therapies for people of all ages and I could not be more excited to join its board of directors as chairman,” said Mr. Nicholson. “Tovorafenib has the potential to become a meaningful new targeted treatment for pediatric low-grade glioma, a devastating form of childhood brain cancer, and I look forward to applying my oncology market experience as the company prepares for potential commercialization.”
About Tovorafenib Tovorafenib is an investigational, oral, brain-penetrant, highly selective type II pan-RAF kinase inhibitor designed to target a key enzyme in the MAPK signaling pathway, which is being investigated in primary brain tumors and solid tumors harboring activating RAF alterations. Tovorafenib has been studied in over 325 patients to date. Currently tovorafenib is under evaluation in a pivotal Phase 2 clinical trial (FIREFLY-1) among pediatric, adolescent and young adult patients with relapsed pediatric low-grade glioma (pLGG), which is an area of considerable unmet need with no approved therapies for the majority of patients. Day One has also initiated a pivotal Phase 3 study (FIREFLY-2/LOGGIC) in newly-diagnosed patients with pLGG. Beyond pLGG, tovorafenib is being evaluated alone or as a combination therapy for adolescent and adult patient populations with recurrent or progressive solid tumors with MAPK pathway aberrations (FIRELIGHT-1). Tovorafenib has been granted Breakthrough Therapy and Rare Pediatric Disease designations by the U.S. Food and Drug Administration (FDA) for the treatment of patients with pLGG harboring an activating RAF alteration. Tovorafenib has also received Orphan Drug designation from the FDA for the treatment of malignant glioma, and from the European Commission (EC) for the treatment of glioma.
Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company that believes when it comes to pediatric cancer, we can do better. We put kids first and are developing targeted therapies that deliver to their needs. Day One was founded to address a critical unmet need: the dire lack of therapeutic development in pediatric cancer. The Company’s name was inspired by the “The Day One Talk” that physicians have with patients and their families about an initial cancer diagnosis and treatment plan. Day One aims to re-envision cancer drug development and redefine what’s possible for all people living with cancer—regardless of age—starting from Day One.
Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important emerging cancer treatments. The Company’s lead product candidate, tovorafenib (DAY101), is an investigational, oral, brain-penetrant, highly-selective type II pan-RAF kinase inhibitor. The Company’s pipeline also includes pimasertib, an investigational, oral, highly-selective small molecule inhibitor of mitogen‐activated protein kinases 1 and 2 (MEK-1/-2). Day One is based in South San Francisco. For more information, please visit www.dayonebio.com or find the company on LinkedIn or Twitter.
Cautionary Note Regarding Forward-Looking Statements This press release contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: Day One’s plans to develop cancer therapies, expectations from current clinical trials, the execution of the Phase 2 and Phase 3 clinical trial for tovorafenib (DAY101) as designed, any expectations about safety, efficacy, timing and ability to complete clinical trials, release data results and to obtain regulatory approvals for tovorafenib (DAY101) and other candidates in development, and the ability of tovorafenib (DAY101) to treat pLGG or related indications.
Statements including words such as “believe,” “plan,” “continue,” “expect,” “will,” “develop,” “signal,” “potential,” or “ongoing” and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements.
Forward-looking statements are subject to risks and uncertainties that may cause Day One’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties in this press release and other risks set forth in our filings with the Securities and Exchange Commission, including Day One’s ability to develop, obtain regulatory approval for or commercialize any product candidate, Day One’s ability to protect intellectual property, the potential impact of the COVID-19 pandemic and the sufficiency of Day One’s cash, cash equivalents and investments to fund its operations. These forward-looking statements speak only as of the date hereof and Day One specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise, except as required by law.
Media: 1AB Dan Budwick dan@1abmedia.com
Investors: LifeSci Advisors Hans Vitzthum hans@lifesciadvisors.com
UBS's Colin Bristow raised his rating on the stock to Buy from Neutral, saying Well Street's expectations for sales of Mounjaro are too low.
Word spread quickly yesterday that almost 1.1 million Tesla (NASDAQ: TSLA) vehicles were being recalled. At the morning's lows, Tesla shares were down just shy of 5%. The stock market isn't always efficient, but simple math indicates that the recall isn't the reason Tesla shares have dropped for a second straight day.
Novavax (NVAX) sinks to a new record level 52-week low after analysts at JP Morgan cut the 12-month target price on the stock by more than $100.
The exclusive licensing agreement with GSK will fund Spero's (SPRO) existing operations and extend its current cash runway beyond 2024.
In this article, we will look at the 4 stocks billionaire Leon Cooperman is talking about right now. If you want to skip reading about Leon Cooperman, his investment career, and his stock-picking strategy, you can go directly to Billionaire Leon Cooperman is Talking About These 2 Stocks. Leon Cooperman’s Investment Career Leon Cooperman is […]
The shipping company has developed a reputation as one of the best dividend stocks around
On Wednesday, the Fed bumped up interest rates again, its third 75-basis point hike since June, and signaled that there could be two more such hikes by the end of this year. The conventional wisdom has the Fed acting properly, and aggressively, in an attempt to counter inflation raging at 40-year high levels. But conventional wisdom isn’t always right – and we can learn a lot by consulting the contrarians. Few top investors are more contrarian than Cathie Wood. The founder and manager of ARK Inv
It's Friday morning -- two days after the Federal Reserve raised interest rates 0.75%, and one day after seemingly every other central bank in the world followed suit, according to The Wall Street Journal -- and oil stocks are tanking. As of 9:50 a.m. ET, shares of oil company Occidental Petroleum (NYSE: OXY) are down 5.6%, while industry bellwether ExxonMobil (NYSE: XOM) is down a solid 6%, and refiner Phillips 66 (NYSE: PSX) is leading the pack lower with a 6.7% loss.
Boeing (NYSE: BA) made a big move to put part of its troubled past behind it, but the aerospace manufacturer also apparently has fallen out of favor with what had been a key customer in China. Boeing has taken its investors on a turbulent ride over the past few years. The company's 737 MAX, which was once billed as having the potential to be the top-selling aircraft of all time, was involved in fatal crashes in 2018 and 2019 that led to the plane being grounded for 18 months and prompted a comprehensive review of Boeing's engineering and safety practices.
In this article, we discuss the 11 best commodity stocks to invest in. If you want to read about some more commodity stocks, go directly to 5 Best Commodity Stocks To Invest In. Macroeconomic concerns have been clouding the commodities market in the past few days after the Federal Reserve in the United States hiked […]
In this article, we discuss 10 best stocks to buy before recession begins. If you want to see more stocks in this selection, click 5 Best Stocks to Buy Before Recession Begins. Between 1929 and 1939, the period famously dubbed the Great Depression, global economies suffered from stock market crashes, sharp declines in output, high […]
Stephen Chazen, who rose to the top of Occidental Petroleum during a lengthy career and after his retirement started and ran a Texas shale-oil producer, has died aged 76 after an illness. Chazen was chief executive and chairman of Houston-based Magnolia Oil and Gas Corp, which he helped start in 2017 after leaving Occidental and ran until this week. Chazen, who early in his career was a finance executive, acquired shale properties and pledged to put cash flow above production.
Shares of virtually all oil and gas stocks crashed today, with even those regarded as among the "safest" oil and gas stocks plunging in value. Diversified integrated major and Warren Buffett favorite Chevron (NYSE: CVX) fell 5%, pipeline company Enterprise Products Partners (NYSE: EPD) fell 5.3%, and shale explorer and producer Diamondback Energy (NASDAQ: FANG) fell a whopping 9.5% as of 1:15 p.m. ET. All of these oil and gas-related stocks seem to be following the plunge in oil prices, as November oil futures fell 5.5% at that time to $78.90 as of this writing, similar to the first two stocks.
Shares of recreational vehicle (RV) company Camping World Holdings (NYSE: CWH) crashed on Friday, after an analyst lowered their price target in a research note. As of 1:10 p.m. ET, Camping World stock was down 10%. Truist analyst Michael Swartz has been busily researching the state of the RV market, which led him to lower his target price for Camping World stock.
Shares of the Chinese electric vehicle (EV) maker Nio (NYSE: NIO) were falling this morning on seemingly no company-specific news. Instead, the EV stock is likely falling as the broader market responds to soaring inflation and the Federal Reserve's aggressive interest rate hikes. Investors are getting increasingly concerned about the potential for a global recession, and that sentiment is likely contributing to Nio's share price decline today. The stock fell by as much as 4.9% today and was down by 2.5% as of 11:09 a.m. ET.
Needless to say, this has investors -- especially those looking for dividends -- very interested in energy stocks right now. Two in particular are getting a lot of attention: Chevron (NYSE: CVX) and Enterprise Products Partners (NYSE: EPD). While both Chevron and Enterprise Products are strong companies (I own Enterprise Products, too), there are some characteristics of Phillips 66 that are very compelling.
Netflix Inc. is seeking a new chief accounting officer after its current one quit the role after less than four months.
Yahoo Finance’s Daniel Howley joins the Live show to discuss the chip sector, the impact of a macroeconomic slowdown, and Morgan Stanley lowering its price target on AMD to $95 from $102.
The market has soured on these stocks, but insiders are buying. Is it time to load up on these companies?
The market sell-off in 2022 has been brutal, but the longer you invest, the more you recognize that market corrections are opportunities. If you have more than 10 years until retirement, buying shares of strong companies while their stock prices are down has historically been a smart way to build wealth. If you invest just $500 a month at the historical average annual return of the stock market of 10%, you would have $1.1 million after 30 years.